Two patients receive a diagnosis with apparently similar disease characteristics: comparable stage, comparable markers, the same first-line protocol. One responds well. The other doesn’t. Conventional oncology tends to look for the explanation inside the tumor itself: a different mutation, a resistant clone, an unlucky genetic variant. Tumor biology matters, but it does not operate independently of the physiological terrain in which it exists. That interaction, more than either factor alone, may be where much of the unexplained variability in clinical response actually lives.

The Metabolic Layer: Warburg to Seyfried

The terrain argument in oncology has deep roots. In the 1920s, biochemist Otto Warburg observed that many cancer cells exhibit markedly increased glucose uptake and lactate production even in the presence of adequate oxygen, a metabolic signature now known as the Warburg effect. Warburg himself argued that impaired cellular respiration was causal in malignant transformation, not merely a downstream trait of it.¹ That causal interpretation was largely displaced over the following decades as the somatic mutation model came to dominate cancer research.

More recently, researcher Thomas Seyfried has revived and extended Warburg’s observation. Seyfried has argued that mitochondrial dysfunction and impaired oxidative phosphorylation can precede genomic instability, shifting cells toward greater dependence on fermentable fuels and creating conditions that favor malignant transformation, with genetic mutations arising as a downstream consequence rather than the initiating event.² This remains a contested interpretation; the dominant cancer model continues to place genomic alterations centrally in malignant transformation. But Seyfried’s thesis has been influential in shifting some integrative oncology practice toward metabolic interventions such as therapeutic ketosis, calorie restriction, and glucose-targeting strategies among them.²

It’s worth noting that the mainstream view is no longer a simple genetics-versus-metabolism debate. Contemporary cancer biology already recognizes extensive interaction among genomic alterations, metabolism, epigenetics, immune signaling, and the tumor microenvironment.³ Modern oncology has, in other words, already moved toward systems complexity. What Systems Homeostasis asks is that this systems thinking be extended further, beyond the tumor and its immediate microenvironment, to the physiological state of the whole organism.

We aren’t writing this article to argue Seyfried is right. We’re using his work to illustrate why the biological context surrounding a cell matters, while noting that metabolism itself is only one dimension of that context. Treated in isolation, the metabolic model still risks becoming just another single-variable explanation: trading “which gene” for “which pathway.”

From Metabolism to Terrain

Oncology already has language for context. The tumor microenvironment (the immediate milieu of stromal cells, vasculature, immune infiltrate, and signaling molecules surrounding a tumor) is well established as a determinant of tumor behavior and treatment response.^3,4 It is, in effect, a local terrain.

But terrain, in the Systems Homeostasis sense, is larger than the tumor microenvironment. It is not confined to the tissue immediately surrounding the malignancy. Terrain is the dynamic physiological state of the whole organism, through which therapeutic inputs are expressed. Redox balance, immune surveillance, inflammatory tone, endocrine signaling, circadian regulation, and systemic adaptive reserve all shape how an input is received, and each reflects physiological processes extending well beyond the tumor site.

Response = Input × Terrain

Consider two patients with apparently similar disease characteristics, given the same chemotherapy regimen. The input is comparable. The response differs: in therapeutic effect, in tolerance, in toxicity, in recovery. Why? Because terrain is not. Terrain can influence therapeutic response, treatment tolerance, immune competence, recovery, toxicity, and metabolic adaptation. The degree of evidence varies across these domains, and the model does not claim that terrain alone determines whether a malignancy itself resolves or progresses; it claims only that terrain is a significant, underexamined variable in what happens after an input is introduced.

The Problem Chemotherapy Makes Visible

Chemotherapy creates a controlled physiological stress intended to exploit vulnerabilities in malignant cells. The same stress, depending on agent and regimen, can also impose demands on healthy tissue, immune function, and systemic regulatory capacity. The clinical outcome, then, reflects two related but distinct variables: the tumor’s susceptibility to the therapeutic input, and the host’s capacity to tolerate, adapt to, and recover from that same input.

That second variable is where reserve enters, not as a synonym for health but as a specific, if incompletely measured, physiological property: the capacity of regulatory systems to absorb a stressor and return to functional stability without cascading dysregulation elsewhere. Oncology already recognizes important aspects of this problem. Prospective studies of older adults receiving chemotherapy demonstrate substantial variability in severe toxicity and show that patient characteristics beyond conventional performance status contribute useful predictive information.^5,6 Current ASCO guidance similarly recommends geriatric assessment because it identifies vulnerabilities not routinely captured by standard oncology assessment.⁷

Two patients can therefore share similar performance status and unremarkable routine labs while holding very different degrees of this capacity. One completes treatment with manageable toxicity and recovers well between cycles. Another, appearing comparably fit at baseline, develops substantial toxicity, prolonged recovery, and dose delays or reductions that compromise treatment intensity.

What are we failing to measure when two apparently comparable patients demonstrate radically different capacities to respond to the same physiological challenge?

Reserve, in this sense, is not a single measurable quantity but a composite property, expressed differently depending on which regulatory system is under load. Hematopoietic reserve influences marrow recovery between cycles. Hepatic and renal function, drug-metabolizing enzymes, transport systems, and individual pharmacokinetics influence drug handling and clearance. Renal and hepatic function in particular are established determinants of anticancer-drug exposure and may require substantial dose adjustment when impaired.⁸ Redox capacity influences the ability to manage oxidative challenge and maintain cellular homeostasis under treatment-related stress. Immune regulatory capacity contributes to both antitumor surveillance and resilience during treatment-associated immunosuppression. Autonomic and endocrine regulation may further influence systemic adaptation to treatment-related stress. None of these dimensions is interchangeable with another, and routine laboratory values and performance status provide only partial windows into them.

Reserve, however, is not static, and this may be the more important point. A patient enters treatment with a given reserve, which can be depleted through repeated physiological stress, partially restored during intervals between cycles, or eroded further as cumulative demands begin to outpace the system’s capacity to recover. This introduces a related but distinct concept: adaptive capacity, not simply how much regulatory reserve is available, but how effectively the system can deploy that reserve and reorganize in response to an ongoing stressor.

This has a direct implication for how Response = Input × Terrain should be understood. It is not only a model for explaining differences between patients; it is also a model for understanding change within a single patient over time. The same therapeutic input delivered at cycle one and cycle six is not necessarily being delivered into the same terrain. The patient receiving cycle six is not physiologically identical to the patient who received cycle one, not in identity, but in the regulatory capacity available to meet that input. Interindividual variability explains why two different patients respond differently to the same treatment. Intraindividual variability over time explains why the same patient’s response can shift over the course of that same treatment.

That offers another lens through which to view a familiar clinical pattern: tolerance early in a regimen giving way to escalating toxicity later. Cumulative tissue injury remains part of the explanation, but from a Systems Homeostasis perspective, repeated treatment may also progressively alter the physiological terrain receiving each subsequent therapeutic input.

Terrain Is a System, Not a Checklist

At this point, it would be reasonable for a reader to conclude that terrain simply means paying attention to a longer list of physiological variables: mitochondrial function, inflammation, hormones, immune regulation, circadian rhythm, nutrient status, and that clinicians working from a functional or integrative framework have already been doing this for years. That conclusion misses what actually distinguishes the model.

Terrain, as used here, is not defined by which variables are considered. It is defined by the relationships among the regulatory domains described above, and by their collective capacity to maintain or restore functional stability as demand changes. A patient can have individually unremarkable values across every domain on a standard workup (normal inflammatory markers, normal thyroid panel, normal complete blood count) while still demonstrating impaired capacity to coordinate an effective response when the system is challenged. Reserve and adaptive capacity, as described earlier, are properties of that coordination. They are not the sum of its individual components, and they are not visible from any single component viewed in isolation.

This points to a practical consequence that runs somewhat against clinical instinct: a biomarker is an observation about the current state of a system. It does not necessarily tell us why that state exists. An elevated inflammatory marker tells us that inflammation is occurring; it does not, by itself, establish the upstream regulatory process responsible for it. Treating the marker without understanding the regulatory context that produced it may change the measurement without necessarily restoring the system’s capacity to respond appropriately to demand.

This is also why static, baseline measurement tells only part of the story. Imagine two patients with identical baseline values across every standard domain. Introduce a physiological demand (a stressor, an illness, a therapeutic input) and one system compensates appropriately, returning toward stability. The other overshoots, fails to compensate adequately, or recovers slowly. That difference was not necessarily visible in either patient’s baseline values. It became visible only in the response to challenge.

This is where Response = Input × Terrain stops functioning only as an explanatory model and becomes a framework for interpreting physiological response. Terrain is therefore characterized not only by what a system measures at rest, but by how it responds when demand is placed upon it.

Circadian oncology provides one established example of the importance of physiological context. Randomized studies of chronomodulated chemotherapy have demonstrated that changing the timing of treatment relative to biological rhythms can alter toxicity while generally maintaining therapeutic efficacy, although results remain heterogeneous and further trials are needed.⁹ Chemotherapy, more broadly, provides an unusually clear (if clinically demanding) example of a substantial, defined physiological challenge delivered on a known schedule. The patient’s response to each cycle is itself a window into terrain that a pre-treatment panel alone cannot provide.

This is also why terrain resists being operationalized as a checklist or protocol. A checklist implies that each domain can be assessed and corrected independently, at rest, with the sum of individual corrections producing systemic stability. Systems Homeostasis proposes instead that stability is best understood through how these domains respond and reorganize under load, not merely through their individual status when unchallenged.

In oncology, this matters because the goal of terrain-directed care is not to normalize every measurable abnormality. It is to preserve or restore the regulatory capacity required for the patient to respond appropriately to treatment, including tolerating the challenge treatment itself represents, and recovering adequately between successive challenges.

Terrain-Directed Care Is Not Alternative Tumor Treatment

None of this argues for treating terrain instead of treating the tumor. Tumor-directed therapy (chemotherapy, radiation, targeted agents, immunotherapy) and host-directed care address different dimensions of the same clinical system, not competing strategies. Framing them as alternatives to one another misrepresents both.

Host-directed strategies might include nutrition, metabolic state, sleep and circadian regulation, physical activity, stress physiology, and structured attention to recovery between treatment cycles. But this list should not be mistaken for a general endorsement. Each of these is only appropriate to the extent it is compatible with the specific cancer and the specific therapy being used.

This is where Response = Input × Terrain becomes self-applying: an intervention intended to support terrain is itself an input, and its effect still depends on the terrain receiving it, including whatever tumor-directed therapy is underway.

Ketosis is not inherently beneficial because it is metabolic. Although ketogenic diets can alter metabolic variables in patients with cancer, clinical evidence remains insufficient to establish them as broadly effective anticancer adjuncts.¹⁰

Antioxidant supplementation is not inherently beneficial because oxidative stress happens to be elevated. Concerns remain that antioxidant supplementation may interact with the mechanisms of some cytotoxic therapies, and prospective observational data from patients receiving chemotherapy for breast cancer have raised concerns regarding recurrence and survival, although the evidence does not justify treating all antioxidants, doses, or treatment contexts as equivalent.¹¹

Exercise is not inherently beneficial at every dose, because exercise is itself a physiological stressor. At the same time, the evidence supporting appropriately prescribed aerobic and resistance exercise during active cancer treatment is sufficiently strong that ASCO recommends it for mitigating several treatment-related effects.¹² The important variable is therefore not whether “exercise is good,” but what dose and form of exercise are appropriate for the patient and treatment context.

Fasting is not inherently beneficial simply because it alters nutrient signaling. A systematic review and meta-analysis of fasting regimens during chemotherapy found no evidence that fasting was superior to non-fasting approaches for preventing chemotherapy toxicity.¹³

Depending on the intervention, these strategies may interact meaningfully with active treatment, through effects on drug metabolism, bleeding risk, therapeutic mechanisms, metabolic demand, or hormone-sensitive disease, and their net effect depends on dose, timing, therapeutic context, tumor biology, and the terrain into which they are introduced.

This is not a caveat added out of caution. It follows directly from the model itself. If terrain determines how any input is received, that applies as much to a supportive intervention as it does to a chemotherapy agent. Integrative oncology, understood this way, is not the practice of adding terrain-supportive interventions to conventional treatment. It is the discipline of evaluating every input, tumor-directed or host-directed, against the terrain it will actually be delivered into.

What This Changes in Clinical Reasoning

None of this resolves into a protocol, and it should not be read as a checklist of what to measure. What it offers instead is a different set of questions to ask before any intervention, tumor-directed or host-directed, is introduced. What is the therapeutic objective? What physiological demand does this intervention impose? What terrain will actually receive it? And how will we know whether that terrain is adapting appropriately, or losing reserve under the cumulative demand of treatment?

One further question follows from the dynamic model developed earlier, and may be the most clinically useful of all: what has changed in this patient’s terrain since the last treatment cycle? A regimen well tolerated at cycle one is being delivered into a physiological system that may no longer resemble the one that received it. Asking the question does not require abandoning established clinical measurements, nor does it imply that every dimension of terrain can currently be quantified. It means treating the patient’s response to each successive input as additional clinically relevant information, rather than assuming tolerance at the outset predicts tolerance throughout.

Conclusion

Return to the two patients this article opened with. Similar diagnosis. Comparable disease characteristics. The same treatment. A different response.

Not because tumor biology doesn’t matter. It does. Not because genetics don’t matter. They do. Not because metabolism, in the tradition of Warburg and Seyfried, explains the whole of it. It explains a part. But because no input, however well chosen, acts independently of the system that receives it.

Response = Input × Terrain.

References